<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03909152</url>
  </required_header>
  <id_info>
    <org_study_id>19-061</org_study_id>
    <nct_id>NCT03909152</nct_id>
  </id_info>
  <brief_title>A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone</brief_title>
  <official_title>Basket Study of the Oral Progesterone Antagonist Onapristone ER (Apristor), Alone or In Combination With Anastrozole in Women With Progesterone Receptor Positive (PR+) Recurrent Granulosa Cell Tumor, Low Grade Serous Ovarian Cancer or Endometrioid Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Context Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test any good and bad effect of the study drug, onapristone&#xD;
      extended-release (ER) alone and in combination with anastrozole.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2, 2019</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A non-randomized, open, multicenter phase 2 study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>within 36 weeks</time_frame>
    <description>as determined by RECIST 1.1 response</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Granulosa Cell Ovarian Cancer</condition>
  <condition>Low Grade Serous Ovarian/ Primary Peritoneal Cancer</condition>
  <condition>Endometrioid Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>PR+ Granulosa cell tumor (This Arm is closed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled patients will initiate treatment with onapristone ER 50 mg by mouth twice daily, about 12 hours apart, beginning Day 1 of Cycle 1. A Cycle is 28 days. This Arm is closed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PR+ Low grade serous ovarian cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled patients will initiate treatment with onapristone ER 50 mg by mouth twice daily, about 12 hours apart, beginning Day 1 of Cycle 1. A Cycle is 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PR+ Endometrioid endometrial cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled patients will initiate treatment with onapristone ER 50 mg by mouth twice daily, about 12 hours apart, beginning Day 1 of Cycle 1. A Cycle is 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PR+ Granulosa cell ovarian cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled patients will initiate treatment with onapristone ER 50 mg by mouth twice daily, about 12 hours apart and anastrozole 1mg po QD in AM beginning Day 1 of Cycle 1. A Cycle is 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Onapristone ER</intervention_name>
    <description>50 mg PO BID (with dosage adjustments) until POD, unacceptable toxicity or withdrawal of consent.</description>
    <arm_group_label>PR+ Endometrioid endometrial cancer</arm_group_label>
    <arm_group_label>PR+ Granulosa cell tumor (This Arm is closed)</arm_group_label>
    <arm_group_label>PR+ Low grade serous ovarian cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Onapristone ER + Anastrozole</intervention_name>
    <description>Onapristone ER Patients will take 50 PO BID in the form of two 20 mg tablets and one 10 mg tablet taken with food and water twice daily. Patients will be prescribed anastrozole 1mg PO QD. Anastrozole will be taken once daily in the AM with patients morning dose of onapristone ER.</description>
    <arm_group_label>PR+ Granulosa cell ovarian cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis at MSK of either (1) granulosa cell ovarian cancer,&#xD;
             (2) low grade serous ovarian/ primary peritoneal cancer, or (3) endometrioid&#xD;
             endometrial cancer; with PR expression ≥1% by IHC on archival tissue taken within the&#xD;
             prior 3 years or new biopsy if no archival tissue is available. IHC results do not&#xD;
             have to be from MSK.&#xD;
&#xD;
          -  Measurable disease as defined by RECIST 1.1. Measurable disease is defined as at least&#xD;
             one lesion that can be accurately measured in at least one dimension. Each lesion must&#xD;
             be ≥10mm when measured by CT or MRI. Lymph nodes must be ≥15mm in short axis when&#xD;
             measured by CT or MRI&#xD;
&#xD;
          -  Patients must have had one prior chemotherapy regimen for management of disease. Note:&#xD;
             additional lines of chemotherapy, biologic or immunotherapy are allowed.&#xD;
&#xD;
          -  Recovery from effects of recent surgery, radiotherapy, or chemotherapy&#xD;
&#xD;
          -  At least 4 weeks out from their last dose of radiation therapy&#xD;
&#xD;
          -  At least 4 weeks post-op from any major surgical procedure&#xD;
&#xD;
          -  At least 3 weeks out from their last dose of chemotherapy and/or biologic/targeted&#xD;
             therapy&#xD;
&#xD;
          -  Must be ≥ 18 years of age&#xD;
&#xD;
          -  Karnofsky Performance Status (KPS) of ≥ 70%&#xD;
&#xD;
          -  Women of child-bearing potential must have a negative pregnancy test within 14 days&#xD;
             prior to commencement of study treatment&#xD;
&#xD;
          -  Women of child bearing potential must use an effective form of contraception during&#xD;
             study and for at least 6 months after completion of study treatment&#xD;
&#xD;
          -  Laboratory Test Findings performed within 14 days prior to initiation of study drug&#xD;
             showing:&#xD;
&#xD;
          -  Bone marrow function:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1,000/mcL&#xD;
&#xD;
               -  Platelets ≥ 75,000/mcL&#xD;
&#xD;
               -  Hemoglobin ≥ 8 g/dL&#xD;
&#xD;
          -  Renal function:&#xD;
&#xD;
             °Creatinine ≤ 1.5 x ULN&#xD;
&#xD;
          -  Hepatic function:&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
               -  AST and ALT ≤ 2.5 x ULN&#xD;
&#xD;
          -  Resolution of all acute toxic effects of prior therapy to NCI CTCAE (Version 5.0)&#xD;
             Grade ≤ 1, with the exception of unresolved Grade 2 neuropathy and Grade 2 alopecia,&#xD;
             which are allowed&#xD;
&#xD;
          -  Patient has recovered from any prior radiotherapy&#xD;
&#xD;
          -  Patients must be able to swallow tablets whole, without crushing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of another invasive malignancy (other than non-melanoma skin cancer or&#xD;
             curatively treated in situ carcinoma) with evidence of disease within the past 3 years&#xD;
&#xD;
          -  History of prior hormonal therapy (i.e., megesterol acetate, tamoxifen or aromatase&#xD;
             inhibitors) for treatment of cancer within 28 days before starting study drug&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographic condition that would&#xD;
             potentially hamper compliance with the study protocol&#xD;
&#xD;
          -  Known brain metastasis which have not been treated or showed stability for ≥ 6 months&#xD;
&#xD;
          -  Patient has received an oral or IV corticosteroid within the prior 28 days and&#xD;
             requires chronic corticosteroid therapy (excludes use of steroid premeds for CT&#xD;
             allergy)&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 95mmHg) despite&#xD;
             medical treatment. Patients with a history of hypertension are allowed provided blood&#xD;
             pressure is controlled by anti-hypertensive treatment.&#xD;
&#xD;
          -  Clinically significant heart disease as evidenced by myocardial infarction or arterial&#xD;
             thrombotic event within the past 6 months, severe or unstable angina, or New York&#xD;
             Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction&#xD;
             measurement of &lt; 50% at baseline&#xD;
&#xD;
          -  Refractory nausea and vomiting, requirement for parenteral hydration and/or nutrition,&#xD;
             drainage gastrostomy tube, malabsorption, external biliary shunt, or significant small&#xD;
             bowel resection that would preclude adequate study drug absorption&#xD;
&#xD;
          -  Anticipated or ongoing administration of anti-cancer therapies other than those&#xD;
             administered in this study&#xD;
&#xD;
          -  Use of any prescription medication during the prior 28 days of first onapristone&#xD;
             dosing that the investigator judges is likely to interfere with onapristone activity;&#xD;
             specifically strong inhibitors or inducers, or sensitive substrates of cytochrome P450&#xD;
             CYP3A4. Investigators should consult the following table of clinically-relevant&#xD;
             products http://medicine.iupui.edu/CLINPHARM/ddis/clinical-table.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>GYN cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel Grisham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel Grisham, MD</last_name>
    <phone>646-888-4653</phone>
    <email>grishamr@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chrisann Kyi, MD</last_name>
    <phone>646-888-4221</phone>
    <email>kyic@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Grisham, MD</last_name>
      <phone>646-888-4653</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Grisham, MD</last_name>
      <phone>646-888-4653</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Grisham, MD</last_name>
      <phone>646-888-4653</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Grisham, MD</last_name>
      <phone>646-888-4653</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Grisham, MD</last_name>
      <phone>646-888-4653</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Grisham, MD</last_name>
      <phone>646-888-4653</phone>
    </contact>
    <contact_backup>
      <last_name>Jason Konner, MD</last_name>
      <phone>646-888-4219</phone>
    </contact_backup>
    <investigator>
      <last_name>Rachel Grisham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Rockville Centre</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Grisham, MD</last_name>
      <phone>646-888-4653</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Grisham, MD</last_name>
      <phone>646-888-4653</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 8, 2019</study_first_submitted>
  <study_first_submitted_qc>April 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2019</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Onapristone ER (Apristor)</keyword>
  <keyword>Oral Progesterone</keyword>
  <keyword>Progesterone Receptor Positive (PR+)</keyword>
  <keyword>Anastrozole</keyword>
  <keyword>19-061</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Onapristone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

